Twenty years have passed since the first reports that childhood acute lymphoid leukaemia was no longer incurable (Aur, et al., 1971; Pinkel, 1971a) . A combination chemotherapy and irradiation program consisting of 1 month of remission induction, 1 week of intensive intravenous chemotherapy, 3 weeks of preventive meningeal therapy and 2 to 3 years of continuation chemotherapy resulted in lengthy leukaemia-free survival in one half of the patients. Lancet (1972) called it 'radical treatment,' but approvingly so. The purpose of this essay is to describe some of the important lessons about curing acute leukaemia that have been learned during the past two decades. The lessons discussed will concern the permanence and prevalence of cure, the cure of the child as well as of the leukaemia, the discarding of preventive meningeal irradiation, the limits of intensification of treatment, and the importance of morphology, immunophenotype and genotype in selection and scheduling of treatment.
Permanence and prevalence of cure
The potential permanence of cure of acute lymphoid leukaemia (ALL) was established when it was demonstrated that relapse was rare in children who experienced continuous complete remission for 7 years and were off therapy for 4 years (Pinkel, 1979) . Although the frequency of cure is less in acute myeloid leukaemia (AML), durable complete remission is also evident under similar circumstances . Figure 1 illustrates the event-free survival of the children with ALL in a 1967-68 study, the first to yield a 50% cure rate (Aur et al., 1971; Pinkel, 1987) . These results have been reproduced in numerous institutional and cooperative group studies and there is general consensus that permanent cures can result from modern treatment.
The more difficult issue is the prevalence of cure. National biostatistics in the United States and the United Kingdom indicate that childhood mortality from acute leukaemia has been halved in the past 20 years while incidence is unchanged (Miller & McKay, 1984; Birch et al., 1988 (Lipshultz et al., 1991) . Etoposide and teniposide, used in high total cumulative doses, have been implicated in secondary acute leukaemia, often demonstrating chromosomal translocations with an llq23 breakpoint (Ratain et al., 1987) .
The current therapeutic intervention in childhood leukaemia exhibiting the most severe adverse sequelae is total body irradiation (TBI), myeloablative chemotherapy and allogeneic bone marrow transplantation (Kolb & Bender- (Pinkel, 1989 In summary, during the past 20 years much has been learned about the adverse sequelae of leukaemia therapy. These can result in children cured of leukaemia, but possibly not cured as children. They can be burdened permanently with a legacy of growth, endocrine and neuropsychological disturbances, organ failure and high risk for second cancers. For this reason it is obligatory that the risks of specific agents or modalities precluding cure of the child be weighed carefully with their potential benefit in prolonging leukaemiafree survival. When treatment with high risk of serious adverse sequelae is little or no more effective than low risk treatment, the low risk treatment needs to be chosen because it is the more curative. given various dosages of methotrexate (amethopterin) and their survivals measured. Increased dosage resulted in increased survival until excessive dosage and its toxicity led to shortened survival (Goldin et al., 1956 ).
Discarding preventive meningeal irradiation
One of the key features of successful curative therapy 20 years ago was meningeal irradiation, with or without intrathecal chemotherapy, to prevent primary meningeal relapse (Aur et al., 1971) . Its value was demonstrated in a randomised comparative study initiated shortly after a pilot study suggested it. However, a subsequent comparative study by the Paediatric Oncology Group (POG) revealed that a three drug combination of methotrexate, hydrocortisone, and cytarabine, injected intrathecally during remission induction and periodically during the next 2 years of continuation chemotherapy, was therapeutically equivalent to cranial irradiation and intrathecal methotrexate (Sullivan, et al., 1982) . In a recent POG pilot study in which intermediate high dose methotrexate and cytarabine were administered as well as three drug intrathecal therapy, only three of 99 patients developed primary meningeal relapse (Krance et al., 1991) . In the last 5 years of experience at M.D. Anderson Cancer Center there has been no instance of isolated primary meningeal relapse in children with acute leukaemia who received intrathecal therapy and intermediate high dosage intravenous chemotherapy.
In conclusion, meningeal irradiation with its consequent risks of neuropsychological, growth and neoplastic sequelae, can be omitted when appropriate systemic and intrathecal chemotherapy are utilised.
The limits of intensification of treatment
An important lesson learned in the past 20 years is the self-limiting therapeutic value of increasing the number and dosage of anti-leukaemia agents. Goldin and his colleagues first demonstrated the practical limits of treatment intensification in leukaemia (Figure 2) (Goldin et al., 1956) . Their experiments, using a transplantable leukaemia in inbred mice, showed that increasing the dosage of methotrexate improved survival up to a certain point, beyond which there was progressive shortening of survival with serial increases. There was an optimal dosage of drug above which therapeutic effect was surpassed by toxic effect.
A late 1960's study in children with ALL demonstrated that full, more toxic dosage combination chemotherapy resulted in longer remissions than half, less toxic dosage (Pinkel et al., 1971b) . The need for 'maximum tolerable dosage' was emphasised, therefore, in the curative treatment programs that followed. However, in a 1972-75 study, children with ALL who received two drugs at maximum tolerable dosage had a better chance of surviving in complete remission than those receiving three or four drugs (Figure 3 ) (Aur et al., 1978) . Although the numerical difference was insufficient to be statistically significant, the results suggested that intensification of chemotherapy by use of more drugs might be nonproductive, especially if the additional drugs were less effective and their toxicity overlapped with that of the more effective agents, thus inhibiting their dosage.
Non-comparative studies of ALL have been described in which better remission experience is claimed for use of multiple drugs, including anthracyclines and alkylating agents, rather than simpler antimetabolite regimens (reviewed by Rivera & Mauer, 1987 (Camitta et al., 1989; Land et al., 1989; Krance et al., 1991) . These studies have yielded therapeutic results historically comparable to those of the more extensive multiple drug regimens, but without the liability of their potential adverse sequelae. In summary, there is currently no information to indicate that maximum tolerable dosage of antimetabolite therapy, as currently administered, is of less efficacy in ALL than more extensive multiple drug regimens. However, as indicated further on in this review, this may only be true for the predominating B-precursor ALL of childhood.
In the case of acute nonlymphoid leukaemia, the limits of treatment intensification are more apparent. In three consecutive treatment protocols at one leukaemia center the dosage and number of drugs and the consequent toxicity were markedly increased (Figure 4a ) . However, the plateaus of continuous complete remission for children who received relatively simple, nontoxic, outpatient treatment in earlier years are not significantly different from those who were given complex, highly toxic inpatient-based treatment more recently. The results of consecutively more intense POG treatment programs are strikingly similar (Figure 4b) (Steuber et al., 1990) . Although higher remission induction rates improved short term survival, long term leukaemia-free survival remains approximately the same.
The ultimate in intensification of leukaemia therapy is myeloablative chemotherapy, usually accompanied by lethal TBI, followed by allogeneic, mismatched, or autologous bone marrow transplantation. Again, there appears to be no therapeutic advantage of this method over present current combination chemotherapy regimens that bear considerably less cost in adverse sequelae (Pinkel, 1989a) . This has been demonstrated for ANLL in first remission in children and young adults ( Figure 5 ) (Dahl et al., 1990; Geller et al., 1990;  Remission in years Figure 5a The lengthy complete remission experience of children with acute myeloid leukaemia in first remission was not significantly different for allogeneic marrow transplants vs chemotherapy alone (Dahl et al., 1990) . b, Young adults in first remission of acute myeloid leukaemia had similar cure rates whether treated with chemotherapy-conditioned allogeneic marrow transplants or intensive chemotherapy alone (Geller et al., 1990 (Figure 7 ) (Rivera et al., 1986; Sallan et al., 1989 . b, Consecutive treatment regimens of the Paediatric Oncology Group for children with acute myeloid leukaemia show similar cure rates despite improvements in short term survival (Steuber et al., 1990 ).
The importance of morphology, immunophenotype and genotype in selection and scheduling of treatment Early in the development of chemotherapy of acute leukaemia it became apparent that acute myeloid leukaemia (AML) was less responsive to prednisone, methotrexate and mercaptopurine than ALL. When daunorubicin and cytosine arabinoside became available and were found to be highly effective for inducing remission of AML, it became apparent that morphology was a key determinant in selection of antileukaemia drugs. In the 1970's it became standard practice to use different treatment protocols for AML vs ALL. Among the morphological subtypes of AML, the monocytoid and myelomonocytoid varieties appeared to be more sensitive to the epipodophyllotoxins, etoposide and teniposide. In 1975 thymic precursor ALL was identified as a distinct clinical and biological subclass of morphological ALL, associated with short remissions and a low cure rate when treated Leukaemia-free survival (LFS) in young German adults with acute lymphoid leukaemia was similar whether treated with chemotherapy alone or myeloablation and allogeneic marrow transplant (Horowitz et al., 1991 (Pui et al., 1988 (Pinkel, 1987 Years Figure 7a Second remissions of acute lymphoid leukaemia in children treated with chemotherapy depended on duration of first remission (Rivera et al., 1986) . first remission ) 18 months; ---first remission < 18 months). b, Remission experience of comparable children who received myeloablation and purged marrow autografts was no different (Sallan et al., 1989). according to standard protocols for ALL (Sen & Borella, 1975) . The hypothesis was proposed that immunophenotype might be a determinant of chemotherapy sensitivity of ALL and a criterion for selection of drug treatment (Pinkel, 1979) . This hypothesis was supported by studies in mice which demonstrated that thymic leukaemia was more sensitive to cyclophosphamide and cytarabine than methotrexate and mercaptopurine (Frei et al., 1974) . A comparative clinical Months in continuous complete remission Figure 8a Children with non-T lymphoid leukaemia were not benefited by addition of cyclophosphamide and cytarabine to their continuation chemotherapy (Lauer et al., 1987) . b, For T-cell lymphoid leukaemia, only children who received cyclophosphamide and cytarabine remained in remission (Lauer et al., 1987) . cells of similar morphology and immunophenotype. Further support for this concept is the observation that acute promyeloid leukaemia with the 15;17 translocation and aberrant messenger RNA for retinoic acid receptor alpha is uniquely responsive to all trans retinoic acid, albeit through a differentiation mechanism (Huang et al., 1988; de The et al., 1990 ). In pilot studies described elsewhere the idea that genotype may be the most important criterion of selecting and scheduling antileukaemia drugs is being explored (Pinkel, 1989b) . A new POG phase 3 comparative study of B precursor ALL uses hyperdiploidy, as indicated by DNA index, to stratify patients. However, none of these features -morphology, immunophenotype or genotype -completely explain differences in curability with specific treatment regimens. Some children with hyperdiploid B precursor ALL experience relapse after treatment that is curative for the vast majority with similar disease. On the other hand, some children with ALL who have translocations associated with poor outcome are cured with treatment that is unsuccessful in most children with the same findings. Obviously, there are important factors in selecting therapy that are yet to be determined.
Summary
The past 20 years of curative therapeutics of childhood acute leukaemia has been largely a period of consolidation of gains, refinement of techniques and dissemination of expertise and technology. However, certain lessons have been learned. First, cure can be permanent but the complexity and cost of curative treatment currently restricts its accessibility; prevention or simple curative treatment is needed.
Secondly, cure of the child demands that the risk of adverse sequelae of treatments be carefully balanced with known therapeutic benefits. Thirdly, preventive meningeal irradiation is no longer required. Fourth, treatment intensification is self-limiting. Adverse reactions can cancel out or exceed therapeutic benefits, resulting in a lower cure rate or a similar cure rate with lower quality of cure. Finally, morphology, immunophenotype and genotype of acute leukaemia are important criteria for selecting and scheduling drug therapy. Genotype may be the most important since leukaemia is a genetic disorder for which morphology and immunophenotype are mere reflections. However, none of these features, individually or together, are sufficient to explain all the difference in outcome among children on a given treatment plan or to completely fulfill the need of criteria for selection of treatment.
Acute leukaemia remains an unsolved problem demanding considerably more basic and clinical research to meet the need for prevention and simple dependable curative treatment.
